Wed, Apr 16, 2014, 11:10 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

stemcellmagnet 29 posts  |  Last Activity: 16 hours ago Member since: Jul 26, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Conclusion
    PURION® processed dHACM retains biologically active growth factors and regulatory factors that are in part responsi- ble for its clinical effectiveness in wound healing. dHACM is a multifaceted tissue graft that has the potential to positively affect at least four distinct physiological processes, including cell proliferation, inflammation, metalloproteinase activity and recruitment of stem cells, all of which are intimately involved in regenerative wound healing and soft tissue repair.

    Sentiment: Strong Buy

  • EpiFix® was evaluated for the presence of growth factors, interleukins (ILs) and tissue inhibitors (TIMPs) of enzymes that degrade the extracellular matrix, or metalloproteinases. Both in vitro and in vivo experiments were conducted, and it was clearly established that:

    PURION® processed dHACM retains biologically active growth factors and regulatory factors that are at least partially responsible for its clinical effectiveness in wound healing;
    dHACM contains one or more soluble factors that stimulate mesenchymal stem cell (MSC) migration and recruitment; and
    dHACM is a multifaceted tissue graft that has the potential to positively affect at least four distinct physiological processes: cell proliferation, inflammation, metalloproteinase activity, and recruitment of stem cells – all of which are integral to regenerative wound healing and soft tissue repair.

    Sentiment: Strong Buy

  • Reply to

    30 million in revs for the 3rd quarter

    by stemcellmagnet Apr 10, 2014 12:30 PM
    stemcellmagnet stemcellmagnet Apr 10, 2014 12:39 PM Flag

    I concurr
    in addition they will not take injectable off the market. not a chance

  • Each sales guy does $85,000 a month after they have been hired for 6 months. 120 sales guys today. If you go out 6 months out puts us in 3rd quarter around 30 million.

    Sentiment: Strong Buy

  • Pete is killing it! What more could you ask for?

    Sentiment: Strong Buy

  • Guys a Dirtball. Just got a new Yahoo name and is reposting old info 1/2 of which is bogus! the stock will do what it is going to do but beware of these clowns!

    Sentiment: Strong Buy

  • stemcellmagnet by stemcellmagnet Mar 26, 2014 7:21 AM Flag

    When investing in a company you would like to see management invest or at least have a slug of Equity so that they have Skin in the Game. Pete Petit has invested north of 11 million dollars and Bill and Michael Senken continue to buy more Stock and exercise thier options. When Mimedx's was low on cash Pete was there to step in and loan the company cash in addition set up a 3 million dollar credit facility. By the way he did this in a very fair manner. He could have made a high interest demand etc.. but he didn't . He got 5% if I recall. Now we live in a world where CEO's like Pete Petit are hard to come by. Especially when dealing with the social media that gives rise to #$%$ like the street sweepers of the world. The reality as Pete said this is a disruptive technology and we will be the market leader at the end of this year. Clear and Simple and by the way Shire that paid 750 mil for Dermagraft you will be giving that company away for zero dollars and pray that Geoff McKay might send you a check. These are all the beginning signs that a Disruptive technology is coming along not to mention how many companys can clain they are growing at such a rapid pace with 80% margins! I know I haven't found one yet!!

    Sentiment: Strong Buy

  • Hunter Adams, founder of thestreetsweeper.org:

    sec.gov/litigation/aljdec/id290bpm.htm

    Links to Manuel Asensio described below.

    -----------

    Also:
    justice.usdoj.gov, search CR-00-1248:
    First United Equities Corporation

    9. The defendant HUNTER ADAMS, in addition to being
    an undisclosed principal of First United, Lexington Capital and
    AGS Financial Group, was a registered representative of First
    United from approximately June 1995 through December 1996.
    HUNTER ADAMS was an associate of the Gambino Organized Crime
    Family.

    -----------

    ajr.org/article.asp?id=4911

    "Hunter Adams, the brains behind The Street Sweeper (thestreetsweeper.org), helped launch the site last year, just eight years after federal prosecutors labeled him an associate of the Gambino crime family in New York. Adams, who was convicted for his role in a massive "pump and dump" scheme involving penny stocks, is still on federal probation for his crime."

    -------------

    The registered agent for the company "AFB Media LLC" is Hope Adams. There is no D&B available, only a P.O. Box. Los Angeles and Hollywood are the home base.

    http://webcache.googleusercontent.com/search?q=cache:irRVkmcE-XQJ:www.corporationwiki.com/New-York/New-York/afb-media-llc/67226246.aspx+&cd=1&hl=en&ct=clnk&gl=us

    "Afb Media LLC has a location in New York, NY. Afb Media LLC has no known officers.Afb Media LLC filed as a Foreign on Wednesday, March 16, 2011 in the state of New York and is currently active. Hope Adams serves as the registered agent for this organization.
    Filings: Foreign (CA - Active)
    Source: California Secretary of State last refreshed Thursday, October 20, 2011"
    --------------

    Whois for thestreetsweeper.org. A similar domain registration for americanfraudfighters.com
    references "AFB Media LLC" with the exact same P.O. Box address as thestreetsweeper.org. Therefore,
    thestreetsweeper.org is indeed "AFB Media LLC". If the whois records change, historical data can
    be obtained from doma

    Sentiment: Strong Buy

  • stemcellmagnet stemcellmagnet Mar 20, 2014 6:20 PM Flag

    Yes I guess you can't post links on message boards. I just learned that as well.

    Sentiment: Strong Buy

  • The Securities and Exchange Commission was smacked down by a federal judge in Atlanta.
    The U.S. District Court for the Northern District of Georgia this week ruled in favor of Larry Schvacho in a insider trading case the SEC filed in July 2012.
    On Jan.7, Judge William S. Duffey, Jr.’s opinion criticized what he described as the SEC’s “overreaching, self-serving interpretation” of evidence, according to a press release.
    The SEC alleged that Schvacho made more than $500,000 dollars in improper profit from trading stock in Comsys IT Partners before a merger announcement in February 2010. The SEC also alleged that he learned of the upcoming transaction from a close friend, then-Comsys CEO Larry Enterline. The judge ruled that the SEC relied on unconvincing circumstantial evidence, adding that it was “implausible” that Enterline, “a business professional with an unblemished history of leadership in the private sector,” placed phone calls about the merger so Schvacho could overhear them, according to Morris, Manning & Martin, LLP.
    “My experience demonstrates serious flaws in the way the SEC approaches some of these highly-questionable cases,” Schvacho said in a statement after the judgment. “They have the use of virtually unlimited taxpayer money, and if they lose there are no negative consequences.”
    Phil W. Hudson is a finance, banking and general assignment reporter.

    Sentiment: Strong Buy

  • I guess we will see whether SEC Chairman Mary Jo White revisits her decision to try more cases, given the unattractive string of losses that is piling up. Most recently, a Federal District Judge in the Northern District of Georgia, after a bench trial, found in favor of defendant Ladislav "Larry" Schvacho, who faced insider trading charges. Mr. Schvacho traded in the shares of Comsys, where his very close friend happened to be the Chief Executive Officer. Problem was, the SEC had no evidence to offer except the trading itself and the fact (but not the substance) of a series of telephone calls and contacts between the friends, such contacts being completely in keeping with the men's usual conduct. Seems these guys routinely kept in close contact by telephone and visited with one another often. Their frequency of communications were not at all unusual and did not change one bit around the time of the trading at issue. In fact, Mr. Schvacho had been trading in his friend's company for many years, but he had never told him for fear of risking their friendship. According to Mr. Schvacho, he traded because he had confidence in his pal's skills and because he believed that Comsys, a specialized staffing company, would benefit from the post-recession upswing. Not surprisingly, the court found the evidence completely lacking.

    Notwithstanding what we're seeing these days from U.S. Attorneys' Offices, aided by wiretaps and cooperating witnesses facing jail time, insider trading allegations are always hard to prove. When I was at the SEC, we knew that bringing some of these cases to trial would be difficult, so we worked hard to get them settled. But you can't settle them all, and when they don't settle, judgment about which cases to fight is crucial. You need to have real evidence: documents, emails or text messages, or a tipper or tippee who is willing to testify. Absent that, these cases can't successfully be tried. Frankly, given the evidence in Schvacho, or the complete

    Sentiment: Strong Buy

  • stemcellmagnet by stemcellmagnet Mar 20, 2014 5:35 PM Flag

    http://dealbook.nytimes.com/2014/02/10/s-e-c-s-losing-streak-in-court-puts-agency-in-spotlight/?_php=true&_type=blogs&_r=0

    Sentiment: Strong Buy

  • This is old news. Pete Petit talked about this back in January 2012. Pete Petit took a lie detector and passed even against his lawyers advice! He was very open about the fact that this was going to trial in the spring or summer of 2014. But most importantly the SEC has lost every case they have brought of this nature in the last couple years. I would expect the same results with Pete Petit's case

    Sentiment: Strong Buy

  • * Important Disclosure: The owners of TheStreetSweeper established a short position in MDXG prior to the publication of this article, and they stand to profit from any future declines in the price of the stock. As a matter of policy, however, TheStreetSweeper prohibits members of its editorial team from taking any financial positions in the companies that they cover. To contact Melissa Davis, senior editor of TheStreetSweeper and the author of this story, please send an email to editor@thestreetsweeper.org.

    Sentiment: Strong Buy

  • Reply to

    Commentary this AM

    by homebuilder_watcher Mar 19, 2014 8:49 AM
    stemcellmagnet stemcellmagnet Mar 19, 2014 9:07 AM Flag

    I would argue that the packaged pricing actually works to Mimedx's benefit. The Dr.s will make more money themselves with Epifix than any other product out in the market, not to mention it has the best results today in the market place. Mimedx basically wrote the rule book on reimbursement in 2014 and forward in skin substitutes.

    Sentiment: Strong Buy

  • inShare
    Fri., Mar. 14, 2014
    PR Accounts on the Move
    By Greg Hazley

    New York Area

    Jacobstahl, New York/MiMedx, processor, marketer and distributor of human amniotic tissue for use in healing, as AOR, following a competitive pitch. Work includes corporate and brand positioning, strategic alliances, patient advocacy and media relations. Partner Sandra Stahl leads the account, reporting to Marlene DeSimone, SVP, corporate strategic development, MiMedx.

    Maybe I am looking into things butI have to believe Pete would not call on the marketing machine unless he was feeling good about his discussions with the FDA

    Sentiment: Strong Buy

  • stemcellmagnet by stemcellmagnet Mar 13, 2014 2:50 PM Flag

    "At this stage, we have secured EpiFix coverage and are receiving reimbursement from approximately 100 commercial health plans and state Medicaid Programs. EpiFix is covered for the Blue Cross and Blue Shield members in 23 states and coverage is provided for the members in more than 65 additional commercial health plans. EpiFix also has coverage from 16 state Medicaid Programs. During the past week, EpiFix coverage was confirmed from four of the above commercial plans and two of the 16 state Medicaid Programs."

    Sentiment: Strong Buy

  • stemcellmagnet by stemcellmagnet Mar 13, 2014 2:41 PM Flag

    Medicaid covers 3,420,858 Florida residents.1
    Medicare covers 3,334,266 Florida residents.2
    Once the Affordable Care Act is fully implemented, more than 2,003,000 Florida residents will finally gain access to quality, affordable healthcare.3
    More than 979,600 Florida residents work in the healthcare and social assistance sector.4 Note: This model assumes that the state expands Medicaid. Governor Rick Scott stated his intent to expand the program

    Sentiment: Buy

  • “As I understand it, Osiris has “pass though” reimbursement price control exemption for 2014 and they are eligible for “pass through” status through the first half of 2015, however 2015 is not guaranteed yet because these type of decisions are made one year at a time by Medicare”

    Statement is INCORRECT!. Pass though status will expire at the end of 2014 Grafix pass through status was received in July 2012 and by current statute, the latest they can have is December 2014. The statute grants a minimum of 2 and a maximum of 3 years of pass through status. CMS only issues pass through status annually, once per calendar year, and they do not extend pass through status for parts of a calendar year. Therefore your statement stating that they will have pass through status the first half of 2015 is factually incorrect. This was specifically discussed in the CMS final rule, released on December 10, 2013 page 591 of the CMS HOPPS FINAL RULE (see for yourself, look at regulations.gov,document#: CMS-2013-0154-0866.) I think it’s fair to assume that Osiris management understands this but simply decided not to discuss it.

    Sentiment: Strong Buy

MDXG
5.77+0.04(+0.70%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Google Inc.
NasdaqGSWed, Apr 16, 2014 4:00 PM EDT
Google Inc.
NasdaqGSWed, Apr 16, 2014 4:00 PM EDT